Innovations in ASD Drug Discovery: Overcoming Challenges and Shaping Future Perspectives
A translational roadmap into rational autism therapeutics—spanning convergent neurobiology, iPSC cerebral organoids, CRISPR perturbations, directed evolution, and biomarker-guided clinical trials.
Discovery
Cover Plate
Mapping the biological convergence of high-confidence ASD risk pathways toward druggable synaptic and metabolic targets.
Unmet Needs
Moving beyond comorbid symptom management to address core social communication and excitatory-inhibitory signaling imbalance.
iPSC Organoids
Patient-derived 3D cortical organoids revealing early neurodevelopmental trajectories unreachable in standard rodent assays.
CRISPR & Evolution
High-throughput Perturb-seq screens and directed evolution engineering precision biologics with cleaner receptor selectivity.
Blood-Brain Barrier
Receptor-mediated transcytosis, nanoparticle shuttles, and intranasal peptide delivery overcoming CNS bioavailability walls.
Adaptive Trials
Biomarker stratification (EEG signatures, metabolomic cohorts, digital phenotyping) rescuing heterogeneous clinical cohorts.
Precision
Chapter 1–3 · Pathophysiology & Unmet Needs
Deconstructs why legacy trial designs failed heterogeneous ASD cohorts and pinpoints convergent mTOR, chromatin, and GABA/glutamate nodes.
Chapter 4–6 · Preclinical Revolution
Patient-specific human cortical organoids, single-cell transcriptomics, and multiplex CRISPR screening pipelines.
Chapter 7–9 · Precision Modalities
Small-molecule allosteric modulators, antisense oligonucleotides, directed-evolution biologics, and CNS delivery vectors.
Chapter 10–12 · Quantitative Trial Design
Integrating circadian SCN biomarkers and stratified endpoints into ethically grounded regulatory pathways.
From the Monograph · Rational Therapeutics
“Accelerating progress in uncovering genetic and neurobiological convergence across Autism Spectrum Disorder finally gives medicinal chemistry a coherent map—transforming fragmented trials into biomarker-stratified precision pharmacology.”